Published in Thyroid Res on April 02, 2009
Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol (2013) 1.14
Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology. Arch Med Sci (2013) 1.05
Predictors of Atrial Fibrillation Recurrence in Hyperthyroid and Euthyroid Patients. Arq Bras Cardiol (2016) 0.91
Association of inflammation with atrial fibrillation in hyperthyroidism. J Geriatr Cardiol (2012) 0.88
Pivotal roles of risk factors for incident atrial fibrillation in patients with newly diagnosed hyperthyroidism. J Geriatr Cardiol (2013) 0.88
Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling. Eur Thyroid J (2015) 0.79
Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study. Evid Based Complement Alternat Med (2015) 0.76
Spontaneous Thyroid Hemorrhage on Chronic Anticoagulation Therapy. Clin Pract (2017) 0.75
Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review. Epilepsy Behav Case Rep (2012) 0.75
Bladder pain syndrome/interstitial cystitis is associated with hyperthyroidism. PLoS One (2013) 0.75
Atrial Fibrillation: The Science behind Its Defiance. Aging Dis (2016) 0.75
Prevalence of right atrial non-pulmonary vein triggers in atrial fibrillation patients treated with thyroid hormone replacement therapy. J Interv Card Electrophysiol (2017) 0.75
Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab (2002) 13.06
The Colorado thyroid disease prevalence study. Arch Intern Med (2000) 7.84
New ideas about atrial fibrillation 50 years on. Nature (2002) 5.84
Thyroid hormone and the cardiovascular system. N Engl J Med (2001) 5.56
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med (1994) 4.74
Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation (1999) 4.00
Thyroid status, cardiovascular risk, and mortality in older adults. JAMA (2006) 3.50
Transient inward current underlying arrhythmogenic effects of cardiotonic steroids in Purkinje fibres. J Physiol (1976) 2.78
Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol (2000) 2.59
Thyroid hormone action in the heart. Endocr Rev (2005) 2.57
The effect of altered thyroid state on atrial intracellular potentials. J Physiol (1970) 2.53
Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) (1991) 2.48
Occult thyrotoxicosis: a correctable cause of "idiopathic" atrial fibrillation. Am J Cardiol (1979) 2.20
Atrial fibrillation after isolated coronary surgery affects late survival. Circulation (2008) 2.02
Arterial embolism in thyrotoxicosis with atrial fibrillation. Br Med J (1977) 1.94
Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol (2002) 1.87
Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res (2001) 1.79
Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovasc Res (2000) 1.68
Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res (2004) 1.67
How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. Arch Intern Med (1996) 1.62
Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med (2007) 1.56
Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab (1997) 1.54
Management of atrial fibrillation in the post-thyrotoxic state. Am J Med (1982) 1.42
The molecular basis of thyroid hormone action. N Engl J Med (1994) 1.40
High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med (2008) 1.39
Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med (1990) 1.37
Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab (1999) 1.36
Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J (2001) 1.33
Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res (1994) 1.27
Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology (1996) 1.20
Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med (2004) 1.18
Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits. Cardiology (1973) 1.14
Biochemical basis of thyroid hormone action in the heart. Am J Med (1990) 1.10
The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab (2003) 1.02
Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab (2002) 1.02
Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade. J Clin Endocrinol Metab (1995) 1.01
Hyperthyroidism and the management of atrial fibrillation. Thyroid (2002) 0.97
Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart (1996) 0.97
Atrial fibrillation and isolated suppression of the pituitary-thyroid axis: response to specific antithyroid therapy. Int J Cardiol (1981) 0.97
Atrial electrophysiology in experimental hyperthyroidism in rabbits. Circ Res (1970) 0.95
The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent. Europace (2008) 0.91
Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology (2000) 0.90
Different gene expression of potassium channels by thyroid hormone and an antithyroid drug between the atrium and ventricle of rats. Jpn Heart J (2003) 0.89
Thyroid hormones as neurotransmitters. Thyroid (1996) 0.87
Activation of electrical triggers of atrial fibrillation in hyperthyroidism. J Clin Endocrinol Metab (2008) 0.86
Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle. Cardiovasc Res (1998) 0.86
Effects of hyperthyroidism on delayed rectifier K+ currents in left and right murine atria. Am J Physiol Heart Circ Physiol (2005) 0.85
Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. Biochem Biophys Res Commun (2003) 0.84
A reevaluation of atrial fibrillation in thyrotoxicosis. Dan Med Bull (1984) 0.83
Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. J Clin Invest (1984) 0.83
Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg (2007) 0.82
Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol (2005) 0.82
[Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function]. Cardiologia (1999) 0.82
Cardiac arrhythmias and heart rate in hyperthyroidism. Am J Cardiol (1989) 0.82
Characteristics of a transient inward current that causes delayed afterdepolarizations in atrial cells of the canine coronary sinus. J Mol Cell Cardiol (1987) 0.81
Continuous 24-hour electrocardiography in thyrotoxicosis before and after treatment. Am Heart J (1986) 0.80
Thyroid hormone regulates expression of shaker-related potassium channel mRNA in rat heart. Biochem Biophys Res Commun (1998) 0.78
Incidence of rhythm disorders in hyperthyrosis with special respect of old age form. Acta Med Hung (1990) 0.77
[Cardiovascular effects of thyroid hormones]. Z Kardiol (1996) 0.77
Clinical significance of serum TSH in euthyroid patients with paroxysmal atrial fibrillation. Yonsei Med J (1995) 0.77
Electrophysiological properties of the fibrillating atrium: implications for therapy. Clin Exp Pharmacol Physiol (1998) 0.77
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Atrial fibrillation after isolated coronary surgery affects late survival. Circulation (2008) 2.02
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Time for new indications for statins? Med Sci Monit (2009) 1.87
Preoperative statin therapy is not associated with a decrease in the incidence of delirium after cardiac operations. Ann Thorac Surg (2012) 1.81
Preoperative n-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology (2010) 1.71
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. J Clin Lipidol (2013) 1.58
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Left ventricular dysfunction and NT-proBNP levels in patients with one-vessel disease after first ST-elevation myocardial infarction treated with primary coronary angioplasty. Kardiol Pol (2009) 1.45
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis. Circ J (2011) 1.41
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Sudden cardiac death in CKD patients. Int Urol Nephrol (2015) 1.39
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Risk factors of atrial fibrillation following coronary artery bypass grafting: a preliminary report. Circ J (2006) 1.18
Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study. Arch Med Sci (2012) 1.17
The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep (2011) 1.17
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Preoperative predictors of delirium after cardiac surgery: a preliminary study. Gen Hosp Psychiatry (2006) 1.14
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci (2012) 1.08
Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol (2010) 1.08
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08
Pleiotropic effects of statins--clinical evidence. Curr Pharm Des (2009) 1.08
The effect of smoking on arterial stiffness. Hypertens Res (2010) 1.07
Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol (2007) 1.07
Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med Sci Monit (2011) 1.07
Letter on 'sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney'. J Hypertens (2013) 1.07
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis (2012) 1.06
Serum uric acid as an independent predictor of early death after acute stroke. Circ J (2007) 1.06
Statins: a sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol (2013) 1.06
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Lipid, blood pressure and kidney update 2013. Int Urol Nephrol (2014) 1.05
Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol (2013) 1.04
An update on biomarkers of heart failure in hypertensive patients. J Hypertens (2012) 1.04
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem (2003) 1.03
Statin therapy in the elderly: a review. Arch Gerontol Geriatr (2009) 1.03
The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol (2013) 1.03
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother (2011) 1.01